计算卡帕单抗的成本。
Counting the cost of caplacizumab.
作者信息
Chaturvedi Shruti
机构信息
Johns Hopkins University School of Medicine.
出版信息
Blood. 2021 Feb 18;137(7):871-872. doi: 10.1182/blood.2020009250.
Abstract
In this issue of Goshua et al present a timely cost-effectiveness analysis of caplacizumab for immune thrombotic thrombocytopenic purpura (iTTP) and conclude that adding caplacizumab to standard-of-care (SOC) therapy with plasma exchange and immunosuppression is not cost-effective based on outcomes including duration of hospitalization and iTTP recurrence.
摘要
在本期杂志中，戈舒阿等人针对卡泊单抗治疗免疫性血栓性血小板减少性紫癜（iTTP）进行了及时的成本效益分析，并得出结论：基于包括住院时间和iTTP复发等结果，在采用血浆置换和免疫抑制的标准治疗（SOC）方案中添加卡泊单抗并不具有成本效益。
相似文献
1
Counting the cost of caplacizumab.计算卡帕单抗的成本。
Blood. 2021 Feb 18;137(7):871-872. doi: 10.1182/blood.2020009250.
2
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.
3
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.
4
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply.卡泊单抗治疗获得性血栓性血小板减少性紫癜。回复。
N Engl J Med. 2019 May 2;380(18):e32. doi: 10.1056/NEJMc1902336.
5
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
6
Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab.卡泊单抗治疗难治性免疫性血栓性血小板减少性紫癜的图示治疗方法。
BMJ Case Rep. 2021 Aug 9;14(8):e245600. doi: 10.1136/bcr-2021-245600.
7
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura.卡泊珠单抗再治疗在免疫性血栓性血小板减少性紫癜真实单中心队列患者中的安全性和有效性
Thromb Res. 2023 Aug;228:189-190. doi: 10.1016/j.thromres.2023.06.018. Epub 2023 Jun 16.
8
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.我们是否应该考虑将 caplacizumab 作为急性血栓性血小板减少性紫癜的常规治疗方法？专家对其利弊的看法。
Expert Rev Hematol. 2024 Jan-Mar;17(1-3):9-25. doi: 10.1080/17474086.2024.2318347. Epub 2024 Feb 20.
9
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al.用卡泊单抗治疗的免疫性血栓性血小板减少性紫癜颅内出血：埃什卡赞等人的评论
J Thromb Haemost. 2021 Oct;19(10):2644-2646. doi: 10.1111/jth.15495.
10
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.卡普拉珠单抗作为一线治疗药物对免疫性血栓性血小板减少性紫癜治疗结局的影响。
J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22.
引用本文的文献
1
The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜研究团队及TTP通路改善了一组血栓性血小板减少性紫癜患者的治疗结果。
PLoS One. 2025 Jun 6;20(6):e0325417. doi: 10.1371/journal.pone.0325417. eCollection 2025.
2
A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021.美国免疫性血栓性血小板减少性紫癜患者的人口统计学和治疗方法的描述性5年分析：一项对2017年至2021年390例疾病发作的多中心研究
J Clin Apher. 2025 Apr;40(2):e70017. doi: 10.1002/jca.70017.
3
Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States.卡泊珠单抗在美国免疫性血栓性血小板减少性紫癜中的成本效益
J Manag Care Spec Pharm. 2025 Mar;31(3):277-288. doi: 10.18553/jmcp.2025.31.3.277.
4
Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura.美国三级医疗保健系统中使用卡普拉珠单抗治疗免疫性血栓性血小板减少性紫癜患者的初步经验。
Ann Hematol. 2024 Nov;103(11):4449-4457. doi: 10.1007/s00277-024-05993-5. Epub 2024 Sep 11.
5
Clinical and economic burden of suspected thrombotic thrombocytopenic purpura in US hospitals.美国医院疑似血栓性血小板减少性紫癜的临床和经济负担。
Am J Health Syst Pharm. 2024 Dec 5;81(24):1278-1287. doi: 10.1093/ajhp/zxae167.
6
Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy.意大利免疫介导性血栓性血小板减少性紫癜患者的真实世界数据分析
J Clin Med. 2024 Feb 27;13(5):1342. doi: 10.3390/jcm13051342.
7
Medical consult: aHUS, TTP? How to distinguish and what to do.医学咨询：非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜？如何鉴别及如何处理。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):745-753. doi: 10.1182/hematology.2023000501.
8
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data.卡泊单抗治疗免疫性血栓性血小板减少性紫癜：真实世界多中心数据。
Front Med (Lausanne). 2023 Oct 11;10:1226114. doi: 10.3389/fmed.2023.1226114. eCollection 2023.
9
Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report.卡泊单抗成功治疗难治性血栓性血小板减少性紫癜（TTP）：一例报告
Cureus. 2023 Jul 25;15(7):e42423. doi: 10.7759/cureus.42423. eCollection 2023 Jul.
10
How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?卡泊西单抗应如何用于治疗免疫性血栓性血小板减少性紫癜？
Ann Blood. 2023 Jun 30;8. doi: 10.21037/aob-21-87. Epub 2022 Apr 1.
本文引用的文献
1
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.卡泊西单抗治疗获得性血栓性血小板减少性紫癜的成本效益
Blood. 2021 Feb 18;137(7):969-976. doi: 10.1182/blood.2020006052.
2
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.国际血栓与止血学会（ISTH）血栓性血小板减少性紫癜治疗指南。
J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010. Epub 2020 Sep 11.
3
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.ADAMTS13 和 VWF 活性指导 aTTP 患者个体化的卡普拉珠单抗治疗。
Blood Adv. 2020 Jul 14;4(13):3093-3101. doi: 10.1182/bloodadvances.2020001987.
4
The high cost of prescription drugs: causes and solutions.处方药的高昂成本：成因与解决方案。
Blood Cancer J. 2020 Jun 23;10(6):71. doi: 10.1038/s41408-020-0338-x.
5
How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.靶向治疗如何打破获得性 TTP 的治疗模式：风险、获益和未知。
Blood. 2019 Aug 1;134(5):415-420. doi: 10.1182/blood.2019000954. Epub 2019 Jun 19.
6
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.
7
TTP: long-term outcomes following recovery.TTP：恢复后的长期预后。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):548-552. doi: 10.1182/asheducation-2018.1.548.
8
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
9
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.获得性严重 ADAMTS13 缺乏相关性特发性血栓性血小板减少性紫癜死亡预测模型的建立和验证：法国 TMA 参考中心经验。
Haematologica. 2012 Aug;97(8):1181-6. doi: 10.3324/haematol.2011.049676. Epub 2012 May 11.
Zotero 插件